【摘要】 目的:探讨不同剂量布地奈德联合孟鲁司特治疗支气管哮喘的疗效。方法:将150例支气管哮喘患者随机分为三组,其中低剂量组(A组)50例,中剂量组(B组)50例,高剂量组(C组)50例,三组患者均给予布地奈德联合孟鲁司特治疗,孟鲁司特剂量均为每晚10 mg,布地奈德剂量分别为A组0.4 mg/次,B组为0.8 mg/次,C组为1.6 mg/次。对比三组患者的临床疗效。结果:C组与B组患者症状与体征消失时间明显早于A组患者,差异有统计学意义(P<0.05),C组患者症状与体征消失时间略晚于B组,差异无统计学意义(P>0.05);治疗后,C组与B组患者肺功能均明显好于B组患者,差异有统计学意义(P<0.05),C组与B组肺功能比较,差异无统计学意义(P>0.05);C组与B组患者炎性因子水平明显低于A组患者,差异有统计学意义(P<0.05),C组与B组炎性因子水平比较,差异无统计学意义;三组患者均未出现明显不良反应。结论:不同剂量的布地奈德联合孟鲁司特均能够改善支气管哮喘患者病情,中等剂量的布地奈德效果最佳,适合用于临床治疗。更多还原

【Abstract】 Objective To investigate the efficacy of different doses of budesonide combined with montelukast in the treatment of bronchial asthma.Method 150 patients with bronchial asthma were randomly divided into 3 groups,including 50 cases in the low dose group(group A),50 cases in the middle dose group(group B),and 50 patients in the high dose group(group C).3 patients were treated with budesonide combined with montelukast,the dose of montelukast was 10 mg per night,budesonide dose was 0.4 mg/time in group A,0.8 mg/time in group B The C group was 1.6 mg/time.Compare the clinical efficacy of the three groups of patients.Results The disappearance of symptoms and signs in patients with C and B was significantly earlier than that in group A(P<0.05).The disappearance of symptoms and signs in group C was slightly later than that in group B(P>0.05).After treatment,C The lung function of patients with group B was significantly better than that of group B(P<0.05).There was no significant difference in lung function between group C and group B(P>0.05).The levels of inflammatory factors in group C and group B were significantly lower than those in group A(P<0.05),there was no significant difference in the levels of inflammatory factors between group C and group B;all groups of patients had obvious adverse reactions.Conclusion Different doses of budesonide combined with montelukast can improve the condition of patients with bronchial asthma.The medium dose of budesonide is the best and suitable for clinical treatment.更多还原